Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of Cellectar Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001279704.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
29/41
Latest evidence
08 Jul 2026
- Public ticker
- CLRB on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
29 of 41
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
08 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001279704
- Issuer location
- Florham Park, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Cellectar Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
29/41
Latest evidence
08 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
12 rows are not safely comparable across share classes.
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 41 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 10%.
29 of 41 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
10%
Empery Asset Management, LP
10%
Stonepine Capital Management, LLC
9.9%
Rosalind Advisors, Inc.
5.5%
INTRACOASTAL CAPITAL, LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 41 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
10%
|
$2,347,243
798,382 shares
|
$0 | 29 May 2026 |
| Empery Asset Management, LP |
13D/G
|
10%
|
$2,272,557
864,090 shares
|
$0 | 30 Jun 2026 |
| Stonepine Capital Management, LLC |
13D/G
|
9.9%
|
—
863,277 shares
|
$0 | 04 May 2026 |
| Rosalind Advisors, Inc. |
13D/G
|
5.5%
|
—
247,715 shares
|
$0 | 31 Dec 2025 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
—
140,101 shares
|
$0 | 01 Jul 2025 |
| Orin Hirschman |
13D/G
|
4.9%
|
$586,444
2,022,221 shares
|
$0 | 31 Dec 2024 |
| Hexstone Capital LLC |
13D/G
|
4.9%
|
$553,293
216,130 shares
|
+$169,293 | 31 Dec 2025 |
| Bleichroeder LP |
13D/G
13F
Company
|
4.6%
|
$760,000
200,000 shares
|
$0 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$49,265.
Buys
$49,997
Insiders: 2
Sells
$732
Insiders: 1
Net
+$49,265
Shares: +17,162
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 17,360
Shares: 198
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 17,360 | 0 | $49,997 | $0 | +$49,997 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 198 | $0 | $732 | -$732 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Cellectar Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Jarrod D. Longcor
Net 12M change
+$49,264
Latest report
08 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jarrod D. Longcor | Chief Operating Officer | $58,898 | +$24,998 | +74% | Filing P/S | 07 Jul 2026 |
| James V Caruso | President & CEO, Director | $58,515 | +$24,998 | +75% | Filing P/S | 07 Jul 2026 |
| Andrei Shustov | Senior Vice President, Medical | $15,411 | Mixed | 14 Jun 2024 | ||
| Darrell Shane Lea | Chief Commercial Officer | $11,088 | Mixed | 14 Jun 2024 | ||
| Chad J. Kolean | Cfo | $2,823 | Mixed | 07 Jul 2026 | ||
| John Neis | Director | $36 | -$732 | -95% | Filing P/S | 07 Jul 2026 |
| Andrew Gu | Director | Mixed | 07 Jul 2026 | |||
| Asher Chanan-Khan | Director | Mixed | 07 Jul 2026 | |||
| Douglas J. Swirsky | Director | Mixed | 07 Jul 2026 | |||
| Dov Elefant | Chief Financial Officer | Mixed | 25 Jan 2022 | |||
| Stefan Loren | Consultant | Mixed | 08 Jul 2026 | |||
| Frederick W. Driscoll | Director | Mixed | 07 Jul 2026 |
Recent insider transactions for Cellectar Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Stefan Loren | CLRB | Stock option (right to buy) | Award | 15,000 | 15,000 | 08 Jul 2026 | Direct | |||
| Chad J. Kolean | CLRB | Stock option (right to buy) | Award | 92,000 | 92,000 | 07 Jul 2026 | Direct | |||
| Frederick W. Driscoll | CLRB | Stock option (right to buy) | Award | 25,000 | 25,000 | 07 Jul 2026 | Direct | |||
| Asher Chanan-Khan | CLRB | Stock option (right to buy) | Award | 25,000 | 25,000 | 07 Jul 2026 | Direct | |||
| James V Caruso | CLRB | Stock option (right to buy) | Award | 250,000 | 250,000 | 07 Jul 2026 | Direct | |||
| Andrew Gu | CLRB | Stock option (right to buy) | Award | 25,000 | 25,000 | 07 Jul 2026 | Direct | |||
| Jarrod D. Longcor | CLRB | Stock option (right to buy) | Award | 118,000 | 118,000 | 07 Jul 2026 | Direct | |||
| Douglas J. Swirsky | CLRB | Stock option (right to buy) | Award | 37,500 | 37,500 | 07 Jul 2026 | Direct | |||
| John Neis | CLRB | Stock option (right to buy) | Award | 25,000 | 25,000 | 07 Jul 2026 | Direct | |||
| Jarrod D. Longcor | CLRB | Common Stock | Purchase | 73.7% | $24,998 | $2.88 | 8,680 | 20,451 | 07 May 2026 | Direct |
| Jarrod D. Longcor | CLRB | Warrants | Purchase | 257.6% | 26,040 | 36,149 | 07 May 2026 | Direct | ||
| James V Caruso | CLRB | Common Stock | Purchase | 74.6% | $24,998 | $2.88 | 8,680 | 20,318 | 07 May 2026 | Direct |
| James V Caruso | CLRB | Warrants | Purchase | 259.5% | 26,040 | 36,076 | 07 May 2026 | Direct | ||
| John Neis | CLRB | Common Stock | Sale | -95.2% | $732 | $3.70 | -198 | 10 | 12 Dec 2025 | See Footnote |
* marks a reported price that did not pass the local price check.